Compound Detail
CHEMBL3990034
FIDANACOGENE ELAPARVOVEC 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL3990034 |
| Name | FIDANACOGENE ELAPARVOVEC |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
12
Known Names
3
Indications
1
Mechanisms
Drug Information
| Molecule Type | Gene |
| First Approval | 2024 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Coagulation factor IX exogenous gene | EXOGENOUS GENE | Coagulation factor IX | ✓ | ✓ |
Indications
Hemophilia B Hemorrhage Primary Immunodeficiency Diseases
ATC Classification
B02BD17
fidanacogene elaparvovec
Level 1: BLOOD AND BLOOD FORMING ORGANS
Level 2: ANTIHEMORRHAGICS
Data from ChEMBL 36 via Core Engine